Cargando…
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial
BACKGROUND: Vaccination of human immunodeficiency virus (HIV)-infected infants with bacille Calmette-Guérin (BCG) is contraindicated. HIV-exposed newborns need a new tuberculosis vaccination strategy that protects against tuberculosis early in life and avoids the potential risk of BCG disease until...
Autores principales: | Nemes, Elisa, Hesseling, Anneke C, Tameris, Michele, Mauff, Katya, Downing, Katrina, Mulenga, Humphrey, Rose, Penelope, van der Zalm, Marieke, Mbaba, Sharon, Van As, Danelle, Hanekom, Willem A, Walzl, Gerhard, Scriba, Thomas J, McShane, Helen, Hatherill, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849090/ https://www.ncbi.nlm.nih.gov/pubmed/29028973 http://dx.doi.org/10.1093/cid/cix834 |
Ejemplares similares
-
Tuberculosis vaccines: beyond bacille Calmette–Guérin
por: McShane, Helen
Publicado: (2011) -
Human newborn bacille Calmette–Guérin vaccination and risk of tuberculosis disease: a case-control study
por: Fletcher, Helen A., et al.
Publicado: (2016) -
Bacille Calmette-Guérin: An ophthalmic perspective
por: Jain, Manish, et al.
Publicado: (2022) -
Are Bacille Calmette-Guérin Skin Reactions the Most Important Correlates of Bacille Calmette-Guérin’s Specific and Nonspecific Effects?
por: Schaltz-Buchholzer, Frederik
Publicado: (2022) -
Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
por: Bunyasi, E. W., et al.
Publicado: (2017)